China Genome Editing Market Size & Outlook, 2024-2030

The genome editing market in China is expected to reach a projected revenue of US$ 1,000.0 million by 2030. A compound annual growth rate of 17.6% is expected of China genome editing market from 2025 to 2030.
Revenue, 2024 (US$M)
$378.4
Forecast, 2030 (US$M)
$1,000.0
CAGR, 2025 - 2030
17.6%
Report Coverage
China

China genome editing market highlights

  • The China genome editing market generated a revenue of USD 306.7 million in 2023 and is expected to reach USD 1,000.0 million by 2030.
  • The China market is expected to grow at a CAGR of 18.4% from 2024 to 2030.
  • In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
  • (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.


Genome editing market data book summary

Market revenue in 2023USD 306.7 million
Market revenue in 2030USD 1,000.0 million
Growth rate18.4% (CAGR from 2023 to 2030)
Largest segment(crispr)/cas9
Fastest growing segment(CRISPR)/Cas9
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentation(CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease
Key market players worldwideMerck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc


Other key industry trends

  • In terms of revenue, China accounted for 3.9% of the global genome editing market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China genome editing market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 626.7 million by 2030.

(crispr)/cas9 was the largest segment with a revenue share of 44.54% in 2024. Horizon Databook has segmented the China genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.


Local presence of key market players, such as GenScript, is expected to boost market growth. GenScript is taking initiatives to promote genome engineering services such as CRISPR services and gene services.

For instance, in April 2021, GenScript launched Research-Grade Lentiviral Vector Packaging Service for drug discovery, cell line development, and gene editing. This service allows researchers to package their genetic material of choice, utilizing the company’s proprietary platform to ensure consistent production of functional and intact viruses.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Genome Editing Market Companies

Name Profile # Employees HQ Website

China genome editing market size, by technology, 2018-2030 (US$M)

China Genome Editing Market Outlook Share, 2024 & 2030 (US$M)

China genome editing market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more